


The aim of the fund is to achieve long term growth from investments principally in European equities, excluding the UK.
| Name | % Net Assets |
|---|---|
| Roche | 4.0% |
| Novartis | 3.7% |
| BNP Paribas | 3.1% |
| Novo-Nordisk | 3.0% |
| Telefónica | 2.6% |
| Allianz SE | 2.6% |
| Nordea Bank | 2.5% |
| SAP | 2.4% |
| Ericsson | 2.4% |
| Banco Bilbao Vizcaya Argentaria | 2.3% |
| Key | % Net Assets |
|---|---|
| 4.0% | |
| 3.7% | |
| 3.1% | |
| 3.0% | |
| 86.2% |
| Date | 23-Apr-2020 |
|---|---|
| NAV | 85.36p |
| Currency | GBP |
| Change | -0.46p |
| % | -0.54% |
| YTD change | 85.36p |
| YTD % | n/a |
| Fund Inception | 28/10/2011 |
|---|---|
| Fund Manager | Mark Page / Laurent Millet |
| TER | - |
| Minimum Investment | |
|---|---|
| Initial | £1000 |
| Additional | n/a |
| Savings | £50 |
| Charges | |
|---|---|
| Initial | 5.25% |
| Annual Mang't | 1.50% |
| Exit | n/a |
| Name | % |
|---|---|
| No risk data available. | |
You are here: research